These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36680087)

  • 21. A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus.
    Ouizougun-Oubari M; Pereira N; Tarus B; Galloux M; Lassoued S; Fix J; Tortorici MA; Hoos S; Baron B; England P; Desmaële D; Couvreur P; Bontems F; Rey FA; Eléouët JF; Sizun C; Slama-Schwok A; Duquerroy S
    J Virol; 2015 Nov; 89(21):11129-43. PubMed ID: 26246564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of fingers subdomain-specific monoclonal antibodies inhibiting the hepatitis C virus RNA-dependent RNA polymerase.
    Nikonov A; Juronen E; Ustav M
    J Biol Chem; 2008 Aug; 283(35):24089-102. PubMed ID: 18574240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.
    Luo G; Hamatake RK; Mathis DM; Racela J; Rigat KL; Lemm J; Colonno RJ
    J Virol; 2000 Jan; 74(2):851-63. PubMed ID: 10623748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA.
    Oh JW; Ito T; Lai MM
    J Virol; 1999 Sep; 73(9):7694-702. PubMed ID: 10438859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.
    Sourimant J; Rameix-Welti MA; Gaillard AL; Chevret D; Galloux M; Gault E; Eléouët JF
    J Virol; 2015 Apr; 89(8):4421-33. PubMed ID: 25653447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion.
    Noton SL; Cowton VM; Zack CR; McGivern DR; Fearns R
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10226-31. PubMed ID: 20479224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase.
    Sourimant J; Lieber CM; Yoon JJ; Toots M; Govindarajan M; Udumula V; Sakamoto K; Natchus MG; Patti J; Vernachio J; Plemper RK
    Sci Adv; 2022 Jun; 8(25):eabo2236. PubMed ID: 35749502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.
    Liuzzi M; Mason SW; Cartier M; Lawetz C; McCollum RS; Dansereau N; Bolger G; Lapeyre N; Gaudette Y; Lagacé L; Massariol MJ; Dô F; Whitehead P; Lamarre L; Scouten E; Bordeleau J; Landry S; Rancourt J; Fazal G; Simoneau B
    J Virol; 2005 Oct; 79(20):13105-15. PubMed ID: 16189012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment.
    McCutcheon KM; Jordan R; Mawhorter ME; Noton SL; Powers JG; Fearns R; Cihlar T; Perron M
    J Virol; 2016 Feb; 90(4):1705-17. PubMed ID: 26608311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
    Brookes DW; Coates M; Allen H; Daly L; Constant S; Huang S; Hows M; Davis A; Cass L; Ayrton J; Knowles I; Strong P; Rapeport G; Ito K
    Br J Pharmacol; 2018 Jun; 175(12):2520-2534. PubMed ID: 29579332
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Gao Y; Cao D; Ahn HM; Swain A; Hill S; Ogilvie C; Kurien M; Rahmatullah T; Liang B
    J Biol Chem; 2020 Jan; 295(3):883-895. PubMed ID: 31822560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: A potential approach in RNA interference on viral replication.
    Chin VK; Atika Aziz NA; Hudu SA; Harmal NS; Syahrilnizam A; Jalilian FA; Zamberi S
    J Virol Methods; 2016 Oct; 236():117-125. PubMed ID: 27432115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human Infants.
    Larios Mora A; Detalle L; Van Geelen A; Davis MS; Stohr T; Gallup JM; Ackermann MR
    PLoS One; 2015; 10(12):e0143580. PubMed ID: 26641081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.
    Fearns R; Deval J
    Antiviral Res; 2016 Oct; 134():63-76. PubMed ID: 27575793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unravelling the complexities of respiratory syncytial virus RNA synthesis.
    Cowton VM; McGivern DR; Fearns R
    J Gen Virol; 2006 Jul; 87(Pt 7):1805-1821. PubMed ID: 16760383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Minigenome Systems to Study RSV Transcription.
    Teng MN; Tran KC
    Methods Mol Biol; 2016; 1442():155-64. PubMed ID: 27464693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
    Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
    Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.
    Collins PL; Melero JA
    Virus Res; 2011 Dec; 162(1-2):80-99. PubMed ID: 21963675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the Chemokine Receptor CCR1 and Preferential Recruitment of Gαi Suppress RSV Replication: Implications for Developing Novel Respiratory Syncytial Virus Treatment Strategies.
    Li J; Xue L; Wang J; Meng A; Qiao J; Li M; Wang X; Meng L; Ning J; Gao X; Li W; Ma C; Wei L
    J Virol; 2022 Nov; 96(22):e0130922. PubMed ID: 36317881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.
    Grosfeld H; Hill MG; Collins PL
    J Virol; 1995 Sep; 69(9):5677-86. PubMed ID: 7637014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.